Further lessons from the TGN1412 tragedy

British Medical Journal

Volumn 333, Issue 7562, 2006, Pages 270-271

  Goodyear, Michael D E ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; TGN 1412; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY TGN1412;

ACCIDENT; CLINICAL RESEARCH; CLINICAL TRIAL; CONSULTATION; DATA BASE; EDITORIAL; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; MEDICAL ETHICS; MEDICAL INFORMATION; MEDICAL LITERATURE; MOLECULAR BIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; T LYMPHOCYTE; UNITED KINGDOM; WORLD HEALTH ORGANIZATION; HUMAN EXPERIMENT; STANDARD;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; HUMAN EXPERIMENTATION; HUMANS; PRACTICE GUIDELINES;

EID: 33747203776     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.38929.647662.80     Document Type: Editorial

References (13)

1. Goodyear M. Learning from the TGN1412 trial. BMJ 2006;332:677-8.
2. Medicines and Healthcare Products Regulatory Agency Press release: Latest findings on clinical trial suspension 2006 April 5. www.mhra. gov.uk/home/idcplg?IdcService=SS_GETPAGE&useSecondary=true &ssDocName=CON2023515&ssTargetNodeId=389 (last accessed 27 July 2006).
3. Department of Health. Expert Scientific Group on phase one clinical trials: a consultation, 25 July 2006. www.dh.gov.uk/Consultations/Live Consultations/LiveConsultationsArticle/fs/en?CONTENT_ID=41375 01&chk=x%2BoJ/%2B (last accessed 27 July 2006).
4. Leigh Day and Company. Northwick Park drug trials update, 25 July 2006. www.leighday.co.uk/doc.asp?cat=844&doc=900 (last accessed 27 July 2006).
5. Perks B. Clinical chaos under scrutiny. Chemistry World 25 July 2006. www.rsc.org/chemistryworld/News/2006/July/25070603.asp (last accessed 27 July 2006).
6. Reason J. Human error: models and management. BMJ 2000;320:768-70.
7. Goodyear M. Closing the gaps: moving closer to a collaborative culture: comments on disclosure timing: balancing increased transparency and competitive advantage. World Health Organization Clinical Trials Registry Platform March 31st 2006. http://www.who.int/ictrp/007-Michael_Goodyear_31March06.pdf (last accessed 27 July 2006).
8. Sim I, Chan AW, Gulmezoglu AM, Evans T, Pang T. Clinical trial registration: transparency is the watchword. Lancet 2006;367:1631-3.
9. Downie J. The power of money: commercialization of research conducted in public institutions. Otago Law Rev 2006;11:305-25.
10. Ho MW, Cummins J. London drug trial catastrophe-collapse of science and ethics. Science in Society 2006;30:44-5. www.i-sis.org.uk/LDTC.php (last accessed 27 July 2006).
11. Godlee F. Can we tame the monster? BMJ 2006;8:333.
12. Bickerstaffe R, Brock P, Husson JM, Rubin I, Bragman K, Paterson K, et al. Guiding principles for pharmaceutical physicians from the ethical issues committee of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the UK. Int J Clin Pract 2006;60:238-41.
13. Bickerstaffe R, Brock P, Husson JM, Rubin I, Bragman K, Paterson K, et al. Ethics and pharmaceutical medicine - the full report of the ethical issues committee of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the UK. Int J Clin Pract 2006;60:242-52.